Global Anti-Epileptic Drugs Market, by Generation (First Generation, Second Generation, and Third Generation), by Route of Administration (Oral and Intravenous), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 7,155.6 million in 2019 and is estimated to exhibit a CAGR of 6.6%over the forecast period (2019-2027), as highlighted in a new report published by Coherent Market Insights.

The number of available anti-epilepsy drugs has doubled over the past several decades as the benefits of anti-epilepsy medicines are higher than the possible side-effects from the medicine. Moreover, the U.S. FDA has approved 28 drugs for the treatment of epilepsy and many generic versions of anti-epileptic drugs have been launched by manufacturers.

The U.S. FDA has only approved anticonvulsant medications for seizure disorders in children. Moreover, the currently available newer anti-seizure drugs have simple pharmacokinetics and more limited effects on liver metabolism, thus driving growth of the anti-epileptic drugs market for pediatrics.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/1701

The increasing improvements in efficacy of medications of treating epilepsy is expected to fuel growth of the anti-epileptic drugs market over the forecast period. For instance, newer drugs have exhibited better efficacy, owing to better pharmacokinetic profiles and fewer drug interactions than the classic first-generation drugs. For instance, the third-generation drugs developed by UCB’s Keppra (levetiracetam) and GlaxoSmithKline’s (GSK’s) Lamictal (lamotrigine) transitioned rapidly to the ‘Blockbuster’ status and have replaced the older gold standards in most of the markets as first-line treatments. According to the Epilepsy Foundation report of 2013, the newer third-generation AEDs have provided complete control over seizures to over half of the patients with epilepsy and reduced the number of seizures in another 20-30% of patients, thereby proving the success rate of the newer AEDs.

Browse 35 Market Data Tables and 30 Figures spread through 201 Pages and in-depth TOC on "Global Anti-epileptic Drugs Market, by Generation (First Generation, Second Generation, and Third Generation), by Route of Administration (Oral and Intravenous), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2027"

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/antiepileptic-drugs-market-1701

Key Takeaways of the Global Anti-epileptic Drugs Market:

The global anti-epileptic drug market expected to exhibit a CAGR of 6.6% over the forecast period (2019-2027), owing to emergence of novel efficacious anti-epileptic drugs

Among generation, third generation segment is expected to account for major revenue share by 2027, owing to rising demand for third generation anti-epileptic drugs, which is rapidly outpacing the first generation and second generation anti-epileptic drugs, mostly for the treatment of children and adolescents.

Major players operating in the global anti-epileptic drug market include Novartis AG, GlaxoSmithKline Plc, Johnson & Johnson Service, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Sanofi S.A., Sumitomo Dainippon Pharma Co., Ltd., Mylan N.V., Bausch Health Companies Inc., and UCB S.A.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/1701

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
mailto:[email protected]
U.S. Office:
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737